Experience LANTUS® long-acting (basal) insulin now:
Guidelines for effective once-daily dosing with LANTUS® to initiate in your
insulin-naïve patients and to switch your NPH or premix insulin patients.
*To reduce the risk of hypoglycemia.
Close monitoring under medical supervision is recommended during the transfer and initial weeks thereafter. Dose adjustments of LANTUS®, other insulins, or OADs may be required.
LANTUS® long-acting basal insulin can be administered any time of day. Use LANTUS® once a day at the same time every day
1
- No resuspension required—a clear solution1
- Low variability in absorption and duration of action, regardless of the injection
site1,12
- After injection, LANTUS®, a basal insulin analog,
is slowly released over 24 hours1
Structured titration to target fasting blood glucose:
Below are two suggested options for titrating LANTUS® long-acting (basal) insulin
doses to help patients reach target fasting blood glucose levels.5,13
†Adjust insulin dose subsequently to patient’s need.
‡Dosage was not increased that week if there were any episodes of documented
hypoglycemia (<72 mg/dL) during the preceding week.
From Riddle et al.5
Desired blood glucose levels and the dosage of LANTUS® should be individualized and determined based on the physician's advice in accordance with the needs of the patient.
IMPORTANT SAFETY INFORMATION FOR LANTUS®
LANTUS® is indicated for once-daily subcutaneous administration, at the same
time each day, for the treatment of adult and pediatric patients (6 years and older)
with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who
require basal (long-acting) insulin for the control of hyperglycemia.
LANTUS® SoloSTAR® is a disposable prefilled insulin pen. Needles and the Lantus® SoloSTAR® pen must not be shared.
LANTUS® MUST NOT BE DILUTED OR MIXED WITH ANY OTHER INSULIN OR SOLUTION. If mixed
or diluted, the solution may become cloudy, and the onset of action/time to peak
effect may be altered in an unpredictable manner.
LANTUS® is contraindicated in patients hypersensitive to insulin glargine or
the excipients.
Hypoglycemia is the most common adverse effect of insulin, including LANTUS®.
As with all insulins, the timing of hypoglycemia may differ among various insulin
formulations. Glucose monitoring is recommended for all patients with diabetes.
Any change of insulin type and/or regimen should be made cautiously and only under
medical supervision. Concomitant oral antidiabetes treatment may need to be adjusted.
Other adverse events commonly associated with LANTUS® include the following:
lipodystrophy, skin reactions (such as injection-site reaction, pruritus, rash),
and allergic reactions.
In clinical studies in adult patients there was a higher incidence of treatment-emergent
injection-site pain (2.7% LANTUS® vs 0.7% NPH). The reports of pain at the injection
site were usually mild and did not result in discontinuation of therapy.
Please click here for full prescribing information.
